MX2019001937A - Métodos de tratamiento de trastornos del desarrollo con biguanidas. - Google Patents

Métodos de tratamiento de trastornos del desarrollo con biguanidas.

Info

Publication number
MX2019001937A
MX2019001937A MX2019001937A MX2019001937A MX2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A
Authority
MX
Mexico
Prior art keywords
syndrome
disorder
methods
developmental disorders
biguanides
Prior art date
Application number
MX2019001937A
Other languages
English (en)
Spanish (es)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2019001937A publication Critical patent/MX2019001937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019001937A 2016-08-18 2017-08-18 Métodos de tratamiento de trastornos del desarrollo con biguanidas. MX2019001937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376488P 2016-08-18 2016-08-18
PCT/US2017/047505 WO2018035408A1 (en) 2016-08-18 2017-08-18 Methods of treating developmental disorders with biguanides

Publications (1)

Publication Number Publication Date
MX2019001937A true MX2019001937A (es) 2019-10-02

Family

ID=61190982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001937A MX2019001937A (es) 2016-08-18 2017-08-18 Métodos de tratamiento de trastornos del desarrollo con biguanidas.

Country Status (9)

Country Link
US (2) US10123979B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484452A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019524834A (cg-RX-API-DMAC7.html)
KR (1) KR20190039974A (cg-RX-API-DMAC7.html)
CN (1) CN109715144A (cg-RX-API-DMAC7.html)
AU (1) AU2017313823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3033967A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019001937A (cg-RX-API-DMAC7.html)
WO (1) WO2018035408A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
EP3612190A4 (en) * 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) * 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment
CN113318111B (zh) * 2021-06-21 2026-02-03 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用
US20250041247A1 (en) * 2021-12-01 2025-02-06 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
US20230186023A1 (en) * 2021-12-13 2023-06-15 International Business Machines Corporation Automatically assign term to text documents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
CN102058888B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
EP2653158B1 (en) * 2010-12-13 2017-07-05 Fukuoka University Therapeutic agent for blood-brain barrier disruption syndrome
EP3013371A4 (en) * 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides

Also Published As

Publication number Publication date
CN109715144A (zh) 2019-05-03
US10123979B2 (en) 2018-11-13
US20180050001A1 (en) 2018-02-22
JP2019524834A (ja) 2019-09-05
AU2017313823A1 (en) 2019-02-28
US20190046480A1 (en) 2019-02-14
EP3484452A4 (en) 2020-04-01
KR20190039974A (ko) 2019-04-16
WO2018035408A1 (en) 2018-02-22
CA3033967A1 (en) 2018-02-22
EP3484452A1 (en) 2019-05-22
US10426746B2 (en) 2019-10-01

Similar Documents

Publication Publication Date Title
MX2022004734A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2021217004A3 (en) Methods and compositions for treating virus-associated inflammation
WO2016200101A3 (ko) 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2018226758A3 (en) METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL ORIGIN VESICLES AND TREATMENT OF INFLAMMATION AND NEUROLOGICAL DAMAGE
WO2015067715A3 (en) Gip-glp-1 dual agonist compounds and methods
CA2999253C (en) Heterocyclic compounds and uses thereof
UY36275A (es) Compuestos aminopirimidinilo
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
NZ748016A (en) Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders
WO2018224689A3 (en) SOLID COMPOSITIONS FOR ORAL ADMINISTRATION
AR093705A1 (es) Depsipeptido y sus usos
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2020012989A (es) Agente terapeutico para la fibrosis.
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
MX2020013290A (es) Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo.
MY200499A (en) Sulfonamide pharmaceutical composition
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
WO2019118727A3 (en) Rescue of the pathology of lrrk2 on lysosmes with snx25 or snx27
WO2017184670A3 (en) Methods for treating zika virus infections
MX362905B (es) Tratamiento de combinacion.
WO2018060962A3 (en) Metformin amino acid compounds and methods of using the same
WO2016163818A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
JP2017517574A5 (cg-RX-API-DMAC7.html)
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide